期刊文献+

山东地区多中心胃胃肠间质瘤诊治分析:GISSG1201研究中期报告 被引量:7

Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study
原文传递
导出
摘要 目的分析山东省胃胃肠间质瘤(GIST)的临床病理特点及预后影响因素,以了解山东省胃GIST的诊治现状。方法收集山东省内23家三级甲等医院2001年1月至2014年12月期间手术切除并经病理证实、且完成临床病理学资料复核的1 165例胃GIST病例资料及随访信息,建立数据库,进行回顾性分析。依照美国国立卫生研究院(NIH)于2008年推荐的GIST危险度分级标准对全组病例进行危险度分级。采用Kaplan-Meier法计算患者生存率,分别采用Log-rank检验和Cox风险回归模型进行单因素和多因素预后分析。结果1 165例胃GIST患者中男性557例,女性608例,中位发病年龄60(15~89)岁。肿瘤位于胃底贲门623例(53.5%),胃体346例(29.7%),胃窦196例(16.8%)。行内镜下切除106例,局部切除术589例,胃大部切除术399例,全胃切除术72例。危险度分极:极低危256例(22.0%),低危435例(37.3%),中危251例(21.5%),高危223例(19.1%)。1 116例患者(95.8%)获得随访,随访时间1~60(中位数40)月。随访期间共有337例患者出现复发,中位复发时间为34月(1~60月)。全组患者1、3和5年生存率分别为98.6%、86.1%和73.4%,其中极低危、低危、中危和高危患者5年生存率分别为93.1%、85.8%、63.0%和42.3%,差异有统计学意义(P= 0.000)。多因素预后分析结果显示,肿瘤原发部位(RR= 0.580,95%CI:0.402~0.835)、肿瘤大小(RR= 0.450,95%CI:0.266~0.760)、术中有无肿瘤破裂(RR= 0.557,95%CI:0.336~0.924)、危险度分级(RR= 0.309,95%CI:0.164~0.580)和术后有无服用伊马替尼(RR= 1.993,95%CI:1.350~2.922)是影响胃GIST患者预后的独立因素。结论依据病灶大小选择内镜切除、局部切除、胃大部切除或全胃切除等手术方式均可取得较好的治疗效果。NIH 2008危险度分级标准对我国胃GIST患者的预后有较高的预测价值。肿瘤原� Objective To summarize the treatment status of gastric gastrointestinal stromal tumor (GIST) in Shandong province,by analyzing the clinicopathologieal features and prognostic factors. Methods Clinicopathological and follow-up data of 1 165 patients with gastric GIST between January 2000 and December 2013 from 23 tertiary referral hospitals in Shandong Province were collected to establish a database. The risk stratification of all cases was performed according to the National Institutes of Health (NIH) criteria proposed in 2008. Kaplan-Meier method was used to calculate the survival rate. Log-rank test and Cox regression model were used for univariate and multivariate prognostic analyses. Results Among 1 165 cases of gastric GIST, 557 were male and 608 were female. The median age of onset was 60 (range 15 - 89) years. Primary tumors were located in the gastric fundus and cardia in 623 cases (53.5%), gastric body in 346 cases (29.7%), gastric antrum in 196 cases (16.8%). All the cases underwent resection of tumors, including endoscopic resection (n= 106), local resection (n=589), subtotal gastrectomy(n=399), and total gastrectomy(n=72). Based on the NIH risk stratification, there were 256 cases (22.0%) at very low risk, 435 (37.3%) at low risk, 251 cases (21.5%) at intermediate risk, and 223 cases (19.1%) at high risk. A total of 1 116 cases (95.8%) were followed up and the median follow-up period was 40 (range, 1-60) months. During the period, 337 patients relapsed and the median time to recurrence was 34 (range 1-60) months. The 1-,3-, and 5-year survival rates were 98.6%, 86.1% and 73.4%, respectively. The 5-year survival rates of patients at very low, low, intermediate, and high risk were 93.1%, 85.8%, 65.0% and 42.3% respectively, with a statistically significant difference (P=0.000). Multivariate analysis showed that primary tumor site (RR = 0.580, 95%CI: 0.402 - 0.835), tumor size (RR= 0.450, 95%C1:0.266 - 0.760), intraoperat
出处 《中华胃肠外科杂志》 CAS CSCD 北大核心 2017年第9期1025-1030,共6页 Chinese Journal of Gastrointestinal Surgery
基金 山东省自然科学基金(ZR2013HL045) 山东省重点研发计划项目(2016GGB01022)
关键词 胃肠问质瘤 山东省 危险度分级 外科手术 预后 Gastrointestinal stromal tumors, gastric Shandong Province Risk stratification Surgical procedures Prognosis
  • 相关文献

参考文献1

二级参考文献14

  • 1白月奎,邵永孚,石素胜,高燕宁,孙耘田,程书钧,刘秀云.胃肠道间质瘤预后多因素分析[J].中华肿瘤杂志,2005,27(10):598-601. 被引量:22
  • 2詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 3Cichoz-Lach H,Kasztelan-Szczerbinska B,Slomka M.Gastrointestinal stromal tumors:epidemiology,clinical picture,diagnosis,prognosis and treatment.Pol Arch Med Wewn,2008,118(4):216-221. 被引量:1
  • 4Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:A consensus approach.Hum Pathol,2002,33(5):459-465. 被引量:1
  • 5Bauer S,Corless CL,Heinrich MC,et al.Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.Cancer Chemother Pharmacol,2003,51(3):261-265. 被引量:1
  • 6Mochizuki Y,Kodera Y,Ito S,et al.Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach.World J Surg,2004,28(9):870-875. 被引量:1
  • 7Carboni F,Carlini M,Scardamaglia F,et al.Gastrointestinal stromal tumors of the stomach.A ten-year surgical experience.JExp Clin Cancer Res,2003,22(3):379-384. 被引量:1
  • 8DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival.Ann Surg,2000,231 (1):51-58. 被引量:1
  • 9Croom KF,Perry CM.Imatinib mesylate:in the treatment of gastrointestinal stromal tumours.Drugs,2003,63(5):513-524. 被引量:1
  • 10Miettinen M,Sobin LH,Lasota J.Gastrointestinal stromal tumors of the stomach:a clinicopathologic,immunohistochemical,and molecular genetic study of 1765 cases with long-term follow-up.Am J Surg Pathol,2005,29(1):52-68. 被引量:1

共引文献18

同被引文献51

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部